<DOC>
	<DOC>NCT01070524</DOC>
	<brief_summary>Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with persistent asthma</brief_summary>
	<brief_title>Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma</brief_title>
	<detailed_description>A randomised, double-blind, multinational, multicentre, active-controlled, 3-way cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with moderate or severe persistent asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Moderate or severe asthma partly controlled with ICS or ICS/LABA FEV1 ≥ 60% and ≤ 90% of predicted for the patient normal value Diagnosis of COPD History or current evidence of significant cardiovascular disease Uncontrolled concomitant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>